Get started
Author

Chantal F. Stockem

Observed names: C.F. Stockem, Chantal Stockem, Stockem, C.F.
ORCID: 0000-0002-1782-5039
Observed ORCID: 0000-0002-1782-5039
OpenAlex ID: A5079883164
Turning up the heat: CTLA4 blockade in urothelial cancer
2023 · Chantal F. Stockem, Matthew D. Galsky, et al. · Nature Reviews Urology · 12
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
2026 · Jan-Jaap J. Mellema, Chantal F. Stockem, et al. · Nature Medicine · 11
Intermediate and nonclassical monocytes show heterogeneity in patients with different types of acute coronary syndrome
2017 · Math P. G. Leers, Chantal Stockem, et al. · Cytometry Part A · 10
Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment
2024 · Maksim A. Chelushkin, Jeroen van Dorp, et al. · Clinical Cancer Research · 7
PDF
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial
2023 · C.F. Stockem, J.J.J. Mellema, et al. · Frontiers in Oncology · 6
PDF
1770P Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)
2022 · C.F. Stockem, A. Gil Jimenez, et al. · Annals of Oncology · 4
Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial
2025 · Chantal F. Stockem, Jeroen van Dorp, et al. · European Journal of Cancer · 3
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study
2024 · Chantal F. Stockem, Sarah M. H. Einerhand, et al. · BJC Reports · 3
PDF
1780TiP A phase II clinical study to assess efficacy of induction ipilimumab/nivolumab to spare the bladder in urothelial bladder cancer (INDI-BLADE)
2022 · C.F. Stockem, B.W.G. van Rhijn, et al. · Annals of Oncology · 3
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
2025 · Chantal F. Stockem, Alberto Gil-Jimenez, et al. · Clinical Cancer Research · 2
1768P Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC)
2022 · B.E. Szabados, C.F. Stockem, et al. · Annals of Oncology · 2
MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials
2026 · Joyce Greidanus, Margriet C. van Dijk - de Haan, et al. · European Urology Oncology · 1
PDF
Clinical efficacy and biomarker analysis of pre-operative ipilimumab plus nivolumab in stage III urothelial cancer: The NABUCCO trial update.
2024 · Chantal Stockem, Alberto Gil Jimenez, et al. · Journal of Clinical Oncology · 1
PDF
Optimal use of systemic therapy to improve long-term outcome in locoregionally advanced and metastatic urothelial cancer
2026 · Stockem, C.F. · Leiden Repository (Leiden University)
PDF
Induction ipilimumab plus nivolumab followed by consolidating chemoradiotherapy as bladder-sparing treatment in stage II/III urothelial carcinoma of the bladder: The phase 2 Indi-Blade trial.
2026 · Jan-Jaap Jelmer Mellema, Chantal Stockem, et al. · Journal of Clinical Oncology
P0945 MRI-based response assessment of neoadjuvant systemic immunotherapy in muscle-invasive bladder cancer: Accuracy and reproducibility across 3 prospective clinical trials
2026 · J. Greidanus, M.C. van Dijk - de Haan, et al. · European Urology
Systemic therapy for urothelial cancer: platinum defeated?
2026 · Chantal F. Stockem, Michiel S. van der Heijden · Tijdschrift voor Urologie
PDF
Data from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
2025 · Chantal F. Stockem, Alberto Gil-Jimenez, et al.
Supplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
2025 · Chantal F. Stockem, Alberto Gil-Jimenez, et al.
Supplementary Figure S6 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
2025 · Chantal F. Stockem, Alberto Gil-Jimenez, et al.
Supplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
2025 · Chantal F. Stockem, Alberto Gil-Jimenez, et al.
Supplementary Figure S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
2025 · Chantal F. Stockem, Alberto Gil-Jimenez, et al.
Supplementary Table S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
2025 · Chantal F. Stockem, Alberto Gil-Jimenez, et al.
Supplementary Table S3 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
2025 · Chantal F. Stockem, Alberto Gil-Jimenez, et al.
Supplementary Table S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
2025 · Chantal F. Stockem, Alberto Gil-Jimenez, et al.
Works count: 40
Citation count: 65
H-index: 5
I10-index: 3
Year
Topic
Type